Login to Your Account



Ribozyme Enters Diagnostics Arena Through Fujirebio Deal

By Aaron Lorenzo


Tuesday, March 5, 2002
p class=text> With an eye on penetrating the diagnostic sector, therapeutics firm Ribozyme Pharmaceuticals Inc. reached a deal with a major Japanese company.

Ribozyme entered into an agreement with Fujirebio Inc. to develop and commercialize ribozyme-based clinical diagnostic products, marking the first significant union between Ribozyme and its allosteric ribozyme platform technology with a diagnostics company.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription